Helena Announces Strategic Partnership With Energy Vault
20.7.2021 15:00:00 EEST | Business Wire | Press release
Global problem-solving organization Helena and Energy Vault, the creator of renewable energy storage products that are transforming the world’s approach to utility-scale energy storage for grid resiliency, today announced a strategic partnership to identify additional opportunities for Energy Vault’s breakthrough waste remediation technologies as the company begins deployment of its innovative energy storage system worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005330/en/
Energy Vault Commercial Demonstration Unit - Arbedo-Castione, Switzerland. (Photo: Business Wire)
While supporting Energy Vault’s expansion through Helena’s vast network, the strategic partnership will focus on accelerating adoption by global energy providers of the company’s transformative technology, in particular its advanced material remediation innovations. The unique application of material science to the main energy storage medium – the composite blocks – enables the use of alternative materials to replace environmentally unfriendly substances like concrete, which accounts for 7-8% of greenhouse gas emissions. In addition, the technology can accommodate the recycling of various pre-existing waste materials, which in return helps large utility and industrial companies transform financial and environmental liabilities into infrastructure assets to support their transition to a fully circular economic approach. For example, coal ash waste and retired wind turbine blades can be re-directed from landfills into its custom-made composite blocks that anchor the company’s gravity-powered systems. By maximizing the use of locally sourced soil, sand and waste materials, including outputs from fossil fuel production, Energy Vault’s supply chain design reduces the impact of GHGs from the transport sector while increasing jobs for local economies, the end result being an end-of-life solution for materials that are difficult to break down and can have negative environmental consequences. This beneficial reuse eliminates waste and enables the continual use of local resources within the framework of a circular economy.
This work will build upon the technology and commercial partnership that it previously announced in 2019 with CEMEX Research Group, a subsidiary of global building materials company CEMEX, and supports the collaboration Energy Vault most recently announced earlier this month with leading global energy powerhouse Enel Green Power.
As part of the partnership, which began in late 2020, Helena also announced that it completed a $20 million investment in Energy Vault. Helena’s investment and partnership with Energy Vault is conducted through Helena’s for-profit arm, Helena Special Investments, which operates projects that implement solutions to societal problems through for-profit means. Helena has joined other investors including Saudi Aramco Energy Ventures, SoftBank Vision Fund, CEMEX Ventures, Idealab, and Neotribe Ventures. As part of its investment, Helena Founder and CEO Henry Elkus joined Energy Vault’s board of directors.
"Our job at Helena is to identify and implement solutions to the critical global problems of the next 50 years. It doesn’t get much more critical than radically improving energy storage. It is both a short-term solution to the problems we have seen recently in areas like Texas and a long-term necessity for the world to sustainably transition away from fossil fuels. We believe Energy Vault will play a fundamental role in furthering that transition,” said Helena Founder and CEO Henry Elkus. “We are also supporting Energy Vault’s strategy in addressing another essential problem – remediating waste. The company’s ability to use massive quantities of waste material to construct its systems only makes the impact more real and the business case more viable while also providing utilities a streamlined method to transition out of fossil fuel-based energy production and recycle legacy assets.”
“We are thrilled to partner with Helena in pursuit of our shared mission and mutual passion in accelerating the decarbonization of our planet,” said Robert Piconi, CEO and Co-Founder, Energy Vault. “Given Helena’s focus in taking on the most significant global challenges – in this case the global transition to clean energy production – we are grateful to have them alongside us as both strategic partner and investor. Helena and its global network are already making an impact toward our technology adoption, and our continued work together will help the world to take a vital step towards combating the negative impacts of climate change.”
About Helena
Helena is a global problem-solving organization. Through Helena Projects, Helena seeks to implement solutions to critical societal problems. Since its founding in 2015, Helena Projects have included: America In One Room, which garnered the attention of President Barack Obama and The New York Times for one of the most significant political experiments in U.S. history; Factory in the Sky, which supported the development and construction of the world’s first carbon capture factory; Shield, which worked to protect the electrical grid from foreign and domestic threats; and most recently The Covid Project, which supplied tens of millions units of medical supplies and personal protective equipment to frontline responders during the COVID-19 pandemic. To learn more about Helena, visit helena.org.
About Energy Vault
Energy Vault is the creator of renewable energy storage products that are transforming the world’s approach to utility-scale energy storage for grid resiliency. Applying conventional physics fundamentals of gravity and potential energy, the system combines an innovative crane design that lifts specially designed, massive composite blocks with a proprietary, cloud-based software platform which orchestrates the storage and discharge of electricity. Utilizing 100% eco-friendly materials at unprecedented economics, Energy Vault is accelerating the shift to a fully renewable world.
For more information about Energy Vault, please visit energyvault.com and @EnergyVaultInc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005330/en/
Contact information
Helena Media
Catherine Pope
1.855.438.3553
helena@ellecomm.com
Energy Vault Media
media@energyvault.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
